Sign up USA
Proactive Investors - Run By Investors For Investors

RXi Pharmaceuticals focuses on immuno-oncology, hemp firm switches CEO and why haemorrhoid cream maker is sitting pretty

Proactive's early take on the day's small-cap news ...
skeleton
Body heal thyself - immuno-oncology uses the immune system to combat cancer

Clinical-stage drug developer RXi Pharmaceuticals Corp (NASDAQ:RXII) said it will focus on its “expanding and promising” immuno-oncology programs.

This, according to chief executive Dr Geert Cauwenbergh, “will accelerate growth and in turn support a return on investment for our shareholders”.

"The positive clinical results recently announced from our phase II dermatology study validate the safety and efficacy of our sd-rxRNA therapeutics in humans. These outcomes coupled with robust preclinical results in our immuno-oncology program, further affirm the company's focused development path,” he told the Biotech Showcase Conference.  

“With a much-improved regulatory landscape for the development of cancer therapeutics, we believe that there is great potential for our sd-rxRNA compounds to provide major advances that could change the paradigm in cancer treatments.

“Furthermore, the feedback that we have received, through relationships with leading cancer centers, potential business partners as well as institutional investors, in the context of last week's Biotech Showcase meeting, endorses our sharpened strategy. 

“It is our goal to develop novel immuno-oncology treatments to benefit patients as well as our long-term shareholders and business partners.”

All change at Green Cures

There’s a change of management at Green Cures & Botanical Distribution Inc (OTCMKTS:GRCU) where Joseph Tragesser has resigned as chief executive with William Pitsicalis taking over.

"Joe did great work, and we are very thankful for his tireless efforts in advancing the company towards cannabis and CBD-based objectives," said the new CEO. "We all wish you well in your future endeavors."

The company develops, produces and distributes what it describes as premium hemp-based products.

They are used in medical, skin care, beauty, fashion and lifestyle, branded under the Original Hollywood Hemp logo.

It also develops beverages branded under the Iconic Beverages label.

Haemorrhoid cream green light

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has received a product license in Canada for its lidocaine-based pain cream Xyralid.

It is used for the treatment of haemorrhoids and the sign-off means it can be sold without a prescription.

“We are very happy that Health Canada has approved our Xyralid drug in Canada,” said chief executive, Dr Bassam Damaj.

It is the company’s sixth product on the Canadian market.

Popular on the bulletin boards:

Aphria Inc (OTCMKTS:APHQF)

Friendable Inc (OTCMKTS:FDBL)

Acology Inc (OTCMKTS:ACOL)

FutureLand Corp (OTCMKTS:FUTL)

View full RXII profile View Profile

RXi Pharmaceuticals Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use